Discovery

1. The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan 1/15/2025

   Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.

2. Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams 11/6/2024

   On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial.

3. The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D. 1/29/2025

   Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors.

4. CRI's Response to NIH Cuts with Alicia Zhou, Ph.D. 4/22/2025

   In this episode of the Cell & Gene podcast, Host Erin Harris speaks with Alicia Zhou, Ph.D., CEO of the Cancer Research Institute (CRI), about CRI’s mission to advance cancer immunotherapy and the critical role of federal funding, particularly from the NIH, in supporting basic and translational cancer research.

5. Can Gene Therapy Be The Solution For CHF With AskBio's Dr. Lothar Roessig 12/18/2024

   Lothar Roessig, M.D., SVP, Integrated Product Team Lead, Congestive Heart Failure at Asklepios BioPharmaceutical, Inc. (AskBio) discusses the biggest challenges in developing gene therapies for cardiovascular diseases.

6. The Future of Rare Diseases with The Jackson Laboratory's Rare Disease Translational Center's Cat Lutz 2/27/2024

   Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz.

7. Inside A Dopamine-Restoring Cell Therapy For PD With BlueRock Therapeutics' Dr. Amit Rakhit 12/4/2024

   On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rakhit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of action differs from traditional PD treatments, the limitations of current PD medications, and much more.

8. Pioneering Next-Gen TCR Therapies In Solid Tumors With Neogene Therapeutics' Carsten Linnemann, Ph.D. 10/9/2024

   Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers.

9. Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene 11/20/2024

   Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on-site during the 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies, how globalization impacts patient access, an update on ARM's Grow Internship Program, as well as a few key takeaways from the event that sector professionals can anticipate impacting the CGTs in the next 12 months and beyond.

10. Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita 3/25/2025

    In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics.